Literature DB >> 19576598

[Drug-induced lupus].

Ma Angeles Aguirre Zamorano1, Rosario López Pedrera, Ma Jose Cuadrado Lozano.   

Abstract

Drug-induced lupus (DIL) is syndrome characterised by the occurrence of lupus-like symptoms and serological findings, following exposure to certain drugs. A substantial number of drugs can induce the positivity of antinuclear antibodies (ANA) but the diagnosis of DIL cannot be done in the absence of clinical features. Most patients with DIL have constitutional symptoms, arthralgia or occasionally arthritis, myalgias, fever and weight loss. These features may take weeks or months to develop and use to be mild with renal and central nervous system happening very rarely. ANA are always positive. They are mainly anti-histone proteins. Antibodies to ds-DNA are a rare finding and would tend to favour a diagnosis of idiopathic SLE. They have been associated with the use of tumour necrosis factor inhibitors (ant-TNF) and minocycline. Some drugs can induce particular symptoms o serological abnormalities and the diagnosis may be more difficult. It is the case of minocycline-induced lupus, which uses to affect young women with anti-ds-DNA and p-ANCA antibodies positive and negative anti-histone antibodies. Treatment with anti-TNF alpha is frequently associated with the development of ANA and anti-DNA. The incidence of ANA positive varies between 23-57% and anti-DNA between 9-33%. However, only a small number of patients will develop DIL or vasculitis. Resolution or marked improvement of the symptoms generally occurs within 2-5 weeks of the drugs withdrawal although some patients may require non-steroid anti-inflammatory drug or low dose steroid. Immunosuppressive drugs may be needed in severe cases with renal or neurological involvement. Some patients remain ANA positive for long periods of time. No treatment is necessary for ANA positive in the absence of clinical features. Copyright (c) 2009 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19576598     DOI: 10.1016/j.medcli.2009.04.035

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  4 in total

Review 1.  Drug-induced lupus erythematosus: an update on drugs and mechanisms.

Authors:  Ye He; Amr H Sawalha
Journal:  Curr Opin Rheumatol       Date:  2018-09       Impact factor: 5.006

2.  Disease criteria of systemic lupus erythematosus (SLE); the potential role of non-criteria autoantibodies.

Authors:  Juan Irure-Ventura; Marcos López-Hoyos
Journal:  J Transl Autoimmun       Date:  2022-01-11

3.  Severe lupus induced by the tumor necrosis factor-alpha inhibitor Anbainuo: a case report.

Authors:  Xiaoli Pan; Yuan Yuan; Fei Huang; Mei Tian
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

4.  Clinical Characteristics of Hydralazine-induced Lupus.

Authors:  Homa Timlin; Michael Wu; Monica Crespo-Bosque; Duvuru Geetha; Ashley Ingolia; Uzma Haque; Marilyn C Towns; Thomas Grader-Beck
Journal:  Cureus       Date:  2019-06-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.